Britannia Life Sciences Inc.
BLSIF
$0.0666
-$0.0114-14.62%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.82% | -- | -6.72% | -7.27% | -92.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.82% | -- | -6.72% | -7.27% | -92.17% |
| Cost of Revenue | 146.51% | -- | 16.74% | 5.69% | -88.39% |
| Gross Profit | -71.65% | -- | -18.46% | -12.48% | -93.41% |
| SG&A Expenses | -11.20% | -- | -2.00% | -37.45% | -51.82% |
| Depreciation & Amortization | 5.61% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.58% | -- | 4.36% | -22.97% | -63.94% |
| Operating Income | -7.47% | -- | -602.88% | 84.34% | -152.65% |
| Income Before Tax | 25.05% | -- | -108.66% | -202.93% | -482.27% |
| Income Tax Expenses | -- | -- | 19.13% | 5.47% | -- |
| Earnings from Continuing Operations | 25.05% | -- | -128.00% | -240.79% | -1,126.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -119.84% | -247.26% | 67.69% |
| Net Income | 7.42% | -- | -124.85% | -262.22% | -515.75% |
| EBIT | -7.47% | -- | -602.88% | 84.34% | -152.65% |
| EBITDA | -7.55% | -- | -238.49% | 56.01% | -145.54% |
| EPS Basic | 6.06% | 97.78% | -125.00% | -263.64% | -560.00% |
| Normalized Basic EPS | -127.59% | -- | -233.33% | -241.67% | -625.00% |
| EPS Diluted | 6.06% | 97.78% | -125.00% | -263.64% | -560.00% |
| Normalized Diluted EPS | -127.59% | -- | -233.33% | -241.67% | -625.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |